AU2014230460B2 - Novel binding proteins for PCSK9 - Google Patents

Novel binding proteins for PCSK9 Download PDF

Info

Publication number
AU2014230460B2
AU2014230460B2 AU2014230460A AU2014230460A AU2014230460B2 AU 2014230460 B2 AU2014230460 B2 AU 2014230460B2 AU 2014230460 A AU2014230460 A AU 2014230460A AU 2014230460 A AU2014230460 A AU 2014230460A AU 2014230460 B2 AU2014230460 B2 AU 2014230460B2
Authority
AU
Australia
Prior art keywords
glu
ser
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014230460A
Other languages
English (en)
Other versions
AU2014230460A1 (en
Inventor
Takahide ABURATANI
Andrea ALLERSDORFER
Rachida Siham Bel Aiba
Ryuji Hashimoto
Marlon HINNER
Andreas Hohlbaum
Bradley LUNDE
Gabriele Matschiner
Chikako Nagasaki
Futoshi Nara
Tomohiro Nishizawa
Christine Rothe
Tohru Takahashi
Alexander WIEDENMANN
Shinji Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of AU2014230460A1 publication Critical patent/AU2014230460A1/en
Application granted granted Critical
Publication of AU2014230460B2 publication Critical patent/AU2014230460B2/en
Assigned to PIERIS PHARMACEUTICALS GMBH reassignment PIERIS PHARMACEUTICALS GMBH Request for Assignment Assignors: DAIICHI SANKYO CO., LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2014230460A 2013-03-14 2014-03-13 Novel binding proteins for PCSK9 Ceased AU2014230460B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781511P 2013-03-14 2013-03-14
US61/781,511 2013-03-14
EP13175023 2013-07-04
EP13175023.4 2013-07-04
PCT/EP2014/055013 WO2014140210A1 (en) 2013-03-14 2014-03-13 Novel binding proteins for pcsk9

Publications (2)

Publication Number Publication Date
AU2014230460A1 AU2014230460A1 (en) 2015-09-10
AU2014230460B2 true AU2014230460B2 (en) 2018-04-05

Family

ID=48703321

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014230460A Ceased AU2014230460B2 (en) 2013-03-14 2014-03-13 Novel binding proteins for PCSK9

Country Status (15)

Country Link
US (3) US9150629B2 (enExample)
EP (1) EP2968490A1 (enExample)
JP (1) JP6619650B2 (enExample)
KR (1) KR20150131151A (enExample)
CN (1) CN105246503A (enExample)
AU (1) AU2014230460B2 (enExample)
BR (1) BR112015021681A2 (enExample)
CA (1) CA2905186A1 (enExample)
HK (1) HK1213194A1 (enExample)
IL (1) IL241329A0 (enExample)
MX (1) MX2015012420A (enExample)
PH (1) PH12015501687A1 (enExample)
RU (1) RU2015142437A (enExample)
SG (1) SG11201505856TA (enExample)
WO (1) WO2014140210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
US9398085B2 (en) 2014-11-07 2016-07-19 Ringcentral, Inc. Systems and methods for initiating a peer-to-peer communication session
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
IL278710B2 (en) 2018-05-16 2025-09-01 Lib Therapeutics Llc Compositions comprising pcsk9 binding compounds and methods of use
EP3810176B1 (en) 2018-06-21 2024-12-11 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246387A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
JOP20190150A1 (ar) * 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
EP4470609A3 (en) 2019-01-18 2025-03-12 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN114981288B (zh) * 2020-07-27 2024-05-03 深圳华大生命科学研究院 一种抗体结合的特征性表位及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107563A2 (en) * 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2011154420A2 (en) * 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
NZ508249A (en) 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
AT411852B (de) 2002-02-12 2004-06-25 Didosyan Yuri S Dr Verfahren und vorrichtung zur änderung des polarisationszustandes von licht mit einem magnetisch einachsigen kristall
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
AU2007322265B2 (en) * 2006-11-07 2013-06-20 Merck Sharp & Dohme Corp. Antagonists of PCSK9
EP2083859A4 (en) * 2006-11-07 2010-11-24 Merck Sharp & Dohme PCSK9 ANTAGONISTS
US20100233177A1 (en) * 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
ES2540114T3 (es) 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
EP2802341B1 (en) * 2012-01-09 2019-03-06 Pieris Pharmaceuticals GmbH Methods for preventing, treating or diagnosing disorders
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107563A2 (en) * 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2011154420A2 (en) * 2010-06-08 2011-12-15 Pieris Ag Tear lipocalin muteins binding il-4 r alpha

Also Published As

Publication number Publication date
JP6619650B2 (ja) 2019-12-11
HK1213194A1 (zh) 2016-06-30
US9150629B2 (en) 2015-10-06
CN105246503A (zh) 2016-01-13
WO2014140210A1 (en) 2014-09-18
JP2016519051A (ja) 2016-06-30
PH12015501687A1 (en) 2015-10-19
IL241329A0 (en) 2015-11-30
CA2905186A1 (en) 2014-09-18
US9598476B2 (en) 2017-03-21
US20160024161A1 (en) 2016-01-28
BR112015021681A2 (pt) 2017-11-14
KR20150131151A (ko) 2015-11-24
RU2015142437A (ru) 2017-04-27
EP2968490A1 (en) 2016-01-20
MX2015012420A (es) 2016-06-02
AU2014230460A1 (en) 2015-09-10
SG11201505856TA (en) 2015-08-28
US20170173112A1 (en) 2017-06-22
US20140288008A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
AU2014230460B2 (en) Novel binding proteins for PCSK9
US10898545B2 (en) Tear lipocalin muteins binding IL-4 r alpha
RU2754466C2 (ru) Слитый полипептид с противораковой активностью
JP7108535B2 (ja) Lag-3に特異的な新規タンパク質
AU2009264214A1 (en) Muteins of hNGAL and related proteins with affinity for a given target
WO2011069992A2 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
TW201524994A (zh) Pcsk9新穎結合蛋白
HK1232549A1 (en) Tear lipocalin muteins binding il-4 r alpha

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PIERIS PHARMACEUTICALS GMBH

Free format text: FORMER APPLICANT(S): DAIICHI SANKYO CO., LTD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired